文献速递胸部肿瘤放疗姑息放疗与转移瘤放疗物理与技术

质子治疗或降低免疫检查点抑制剂治疗期间癌症进展风险

Proton Therapy May Reduce the Risk of Cancer Progression During Immune Checkpoint Inhibitor Therapy: A Propensity Score-Matched Analysis of Intensity Modulated Proton Versus Photon Radiation Therapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-10-01

该回顾性研究纳入466例在免疫检查点抑制剂(ICI)治疗期间接受放疗的患者,比较调强质子治疗(IMPT)与调强光子放疗(IMRT)。倾向评分匹配后,IMPT组中位缓解持续时间(17.7 vs 5.7个月)和无进展生存期(18.8 vs 6.8个月)均显著优于IMRT组,且≥2级不良事件更少。

核心结论

  • 与IMRT相比,IMPT与ICI疗效增强相关,可改善DoR和PFS,且不良反应可耐受。
  • 放疗后淋巴细胞计数较高可能与接受IMPT的ICI治疗患者生存改善相关。

研究设计与样本

  • 回顾性分析466例在ICI治疗期间接受放疗的患者,其中IMPT组109例,IMRT组357例。
  • 采用倾向评分匹配平衡临床特征,主要终点为缓解持续时间(DoR),次要终点包括无进展生存期(PFS)和放疗后不良事件。

关键数值与推荐

  • 放疗后淋巴细胞计数二分阈值采用0.5×10^9/L。
  • 亚组分析提示IMPT优于IMRT的获益在Charlson合并症指数≥4、肺癌、晚期疾病或接受姑息、胸部、腹部/盆腔放疗的患者中更明显。

临床怎么用

  • 在ICI治疗期间需放疗的患者中,可考虑优先选用IMPT以延长DoR和PFS并减少不良事件。
  • 对Charlson合并症指数≥4、肺癌、晚期疾病或接受姑息、胸部、腹部/盆腔放疗者,IMPT的相对获益可能更明显。
  • 放疗后淋巴细胞计数(阈值0.5×10^9/L)可能有助于识别IMPT联合ICI治疗获益人群。

局限性

  • 本研究为回顾性分析,可能存在选择偏倚。
  • 样本来自单一时段(2022年7月至2024年9月)的患者数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Intensity modulated proton therapy (IMPT) may preserve the immune response more effectively than intensity modulated photon radiation therapy (IMRT) owing to its dosimetric advantages, making it a potentially superior modality in immunotherapy. This study aimed to evaluate the clinical benefits of IMPT versus IMRT during immune checkpoint inhibitors (ICIs) treatment. METHODS AND MATERIALS: We retrospectively analyzed the data of 466 patients (IMPT group, n = 109; IMRT group, n = 357) who received radiation therapy (RT) during ICI therapy between July 2022 and September 2024. Propensity score matching was applied to balance clinical characteristics. The primary endpoint was the duration of response (DoR). Secondary endpoints included progression-free survival (PFS) and post-RT adverse events. Kaplan-Meier and Cox proportional hazards regression were used to calculate survival curves and identify independent prognostic factors. The threshold used to dichotomize post-RT lymphocyte count was 0.5 × 109/L. RESULTS: Baseline clinical characteristics were balanced after propensity score matching. The IMPT group showed significantly longer median DoR (17.7 vs 5.7 months; P = .0001) and PFS (18.8 vs 6.8 months; P < .0001) than the IMRT group. Multivariable regression revealed IMPT to be an independent predictor of improved DoR (hazard ratio, 0.34; 95% CI, 0.21-0.55; P < .0001) and PFS (hazard ratio, 0.36; 95% CI, 0.25-0.52; P < .0001). Subgroup analyses suggested greater benefit of IMPT over IMRT in patients with a Charlson Comorbidity Index ≥4, lung cancer, advanced-stage disease, or those receiving palliative, thoracic, or abdominal/pelvic RT. Higher post-RT lymphocyte counts in the IMPT group showed potential correlation with improved DoR and PFS. Additionally, the IMPT group had fewer grade ≥2 post-RT adverse events (P = .012). CONCLUSIONS: IMPT is linked to enhanced efficacy of ICIs, compared with IMRT, by improving DoR and PFS with tolerable adverse effects. Higher post-RT lymphocyte counts may be associated with improved survival in patients receiving IMPT during ICI therapy. These findings suggest that IMPT may be a preferable option for preserving immune function, thereby optimizing outcomes during immunotherapy.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Bo C, Lv Z, Zhang H, et al. Proton Therapy May Reduce the Risk of Cancer Progression During Immune Checkpoint Inhibitor Therapy: A Propensity Score-Matched Analysis of Intensity Modulated Proton Versus Photon Radiation Therapy. Int J Radiat Oncol Biol Phys. 2025. PMID: 41043559. doi:10.1016/j.ijrobp.2025.09.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。